Pfizer, Inc. (PFE) Stake Lifted by Huntington National Bank
Huntington National Bank grew its holdings in Pfizer, Inc. (NYSE:PFE) by 1.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,868,974 shares of the biopharmaceutical company’s stock after purchasing an additional 30,501 shares during the quarter. Pfizer comprises about 1.1% of Huntington National Bank’s portfolio, making the stock its 12th biggest position. Huntington National Bank owned approximately 0.11% of Pfizer worth $62,779,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in PFE. Integrated Investment Consultants LLC lifted its stake in shares of Pfizer by 1.6% in the 1st quarter. Integrated Investment Consultants LLC now owns 46,496 shares of the biopharmaceutical company’s stock valued at $1,591,000 after purchasing an additional 750 shares during the period. Private Asset Management Inc. lifted its stake in shares of Pfizer by 1.0% in the 1st quarter. Private Asset Management Inc. now owns 545,684 shares of the biopharmaceutical company’s stock valued at $18,668,000 after purchasing an additional 5,239 shares during the period. Atalanta Sosnoff Capital LLC lifted its stake in shares of Pfizer by 19.7% in the 1st quarter. Atalanta Sosnoff Capital LLC now owns 761,670 shares of the biopharmaceutical company’s stock valued at $26,057,000 after purchasing an additional 125,193 shares during the period. Triangle Securities Wealth Management lifted its stake in shares of Pfizer by 8.4% in the 1st quarter. Triangle Securities Wealth Management now owns 16,764 shares of the biopharmaceutical company’s stock valued at $573,000 after purchasing an additional 1,299 shares during the period. Finally, Cohen Lawrence B acquired a new position in shares of Pfizer in the 1st quarter valued at about $201,000. 69.09% of the stock is currently owned by institutional investors.
In other news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Insiders have sold 426,291 shares of company stock valued at $14,475,911 over the last quarter. Company insiders own 0.06% of the company’s stock.
Shares of Pfizer, Inc. (NYSE PFE) traded up 0.71% during mid-day trading on Friday, reaching $34.23. The company’s stock had a trading volume of 7,069,650 shares. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $34.75. The company has a 50-day moving average of $33.34 and a 200-day moving average of $33.48. The company has a market cap of $203.58 billion, a P/E ratio of 25.04 and a beta of 1.00.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period last year, the business earned $0.64 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. Equities research analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a dividend of $0.32 per share. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.77%. Pfizer’s payout ratio is 94.12%.
A number of research analysts have recently issued reports on PFE shares. Citigroup Inc. downgraded Pfizer from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Morgan Stanley reissued a “neutral” rating and issued a $35.00 price objective (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Jefferies Group LLC reissued a “neutral” rating and issued a $34.00 price objective on shares of Pfizer in a research note on Friday, June 16th. Finally, BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $37.61.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.